作为预后因素的未确定潜力的克隆性血液形成:系统性审查和元分析
Jasmine Singh1,2,3, Nancy Li4, Elham Ashrafi1
1School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
Blood advances
|June 5, 2024
概括
不确定潜力的克隆性血液形成 (CHIP) 增加了死亡,癌症和心血管事件的风险. 了解CHIP的预后影响对于患者护理和风险分层至关重要.
科学领域:
- 血液学 血液学 血液学
- 遗传学 遗传学 是一个
- 在瘤学瘤学.
- 心脏病学 心脏病学
背景情况:
- 测序技术的进步导致了对具有不确定潜力的克隆性血液形成 (CHIP) 个体的识别增加.
- 了解CHIP的预后影响对于临床管理和风险评估至关重要.
研究的目的:
- 系统地审查和综合关于CHIP与各种临床结果之间的关联的证据.
- 量化CHIP患者的不良事件风险,与没有CHIP患者相比.
主要方法:
- 原始研究研究的系统审查和随机效应元分析.
- 搜索了MEDLINE和EMBASE数据库,包括88项研究,超过47万参与者.
- 使用预后因素研究中的质量工具评估偏差风险.
主要成果:
- CHIP与所有原因死亡率 (HR 1.34),癌症死亡率 (HR 1.46),复合心血管事件 (HR 1.40),血液恶性瘤 (HR 4.28) 和严重的COVID-19 (OR 1.46) 的风险增加有关.
- 特定的基因突变 (例如,孤立的DNMT3A) 和克隆大小可能会调解风险.
- 结果的异质性归因于CHIP定义,结果测量和研究群体的变化.
结论:
- CHIP是广泛的不良临床结果的重要风险因素,包括死亡率,癌症和心血管疾病.
- 克隆大小和特定的遗传突变是影响CHIP相关风险的重要因素.
- 需要进一步的研究来完善CHIP的定义和标准化结果评估,以提高预后准确性.
更多相关视频
09:32Clonal Analysis of Embryonic Hematopoietic Stem Cell Precursors Using Single Cell Index Sorting Combined with Endothelial Cell Niche Co-culture
Published on: May 8, 2018
8.6K
14:37Directed Differentiation of Primitive and Definitive Hematopoietic Progenitors from Human Pluripotent Stem Cells
Published on: November 1, 2017
11.0K
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Hematopoiesis
5.2K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.2K
Multipotency of Hematopoietic Stem Cells
3.1K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.1K
Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
Production of Formed Elements
1.4K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
Most HSCs commit to...
1.4K
Role of Hematopoietic Growth Factors
1.4K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.4K
